Collaborative and Other Relationships (Details) $ in Thousands		3 Months Ended
	Nov. 05, 2019 USD ($)	Mar. 31, 2023 USD ($) dose	Mar. 31, 2022 USD ($)
Collaborative and Other Relationships [Line Items]
Revenues		$ 68,778	$ 49,923
U.S. Department of Health and Human Services, net
Collaborative and Other Relationships [Line Items]
Contract term (in years)		5 years
U.S. Department of Health and Human Services, net | Outside of U.S.
Collaborative and Other Relationships [Line Items]
Maximum number of products, doses | dose		50,000
Number of product delivered, doses | dose		49,980
Torii Pharmaceutical Co.
Collaborative and Other Relationships [Line Items]
Revenues	$ 22,000
Potential milestone payments receivable if regulatory approval before specified date	$ 15,000
Maximum customary reduction on royalty rate	50.00%
Royalty payments receivable, expiration term from first commercial (in years)	10 years
Torii Pharmaceutical Co. | Minimum
Collaborative and Other Relationships [Line Items]
Royalty rate if maintains sakigake designation	20.00%
Torii Pharmaceutical Co. | Maximum
Collaborative and Other Relationships [Line Items]
Royalty rate if maintains sakigake designation	40.00%